CORRELATION BETWEEN HOMOCYSTEINE AND GLYCATION MARKERS IN DIABETIC KIDNEY DISEASE PATIENTS
Main Article Content
Abstract
Objective: The study aims to evaluate the correlation between homocysteine (representing inflammation-oxidative stress) and glycation indices (representing glucose metabolism).
Methods: A descriptive cross-sectional study was conducted on 233 patients with diabetic kidney disease aged 18 years and older, who attended outpatient clinics at the Department of General Examination, University Medical Center Ho Chi Minh City - Campus 2. Clinical characteristics such as age, gender, BMI, blood pressure, and duration of type 2 diabetes were recorded, along with paraclinical parameters including blood lipid profile; glycation indices (fasting plasma glucose, HbA1c, fructosamine, and glycation gap); plasma creatinine and cystatin C to assess estimated glomerular filtration rate (eGFR), UACR to assess albuminuria; and homocysteine.
Results: The 233 diabetic kidney disease patients had a mean age of 64.0 ± 10.4 years, with a predominance of females. The mean eGFR was 50.7 ± 25.5 mL/min/1.73 m2, the medan UACR was 341.4 ± 671.5 mg/g, and the mean homocysteine was 14.9 ± 6.2 µmol/L. Homocysteine showed a weak inverse correlation with HbA1c (intracellular glycation) (r = -0.158, p = 0.016) but no correlation with fructosamine (extracellular glycation). Homocysteine also showed a weak inverse correlation with the glycation gap (r = -0.144, p = 0.028).
Conclusion: Homocysteine has a weak inverse correlation with HbA1c and the glycation gap, but no correlation with fructosamine. This suggests that homocysteine may affect stable glycation products (HbA1c), but may not affect glycation products with a short half-life.
Article Details
Keywords
Homocysteine, glycation, HbA1c, fructosamine, glycation gap, diabetic kidney disease.
References
[2] Sinha S.K, Nicholas S.B. Pathomechanisms of diabetic kidney disease. Journal of Clinical Medicine, 2023, 12 (23): 7349.
[3] Nayak A.U, Singh B.M, Dunmore S.J. Potential clinical error arising from use of HbA1c in diabetes: effects of the glycation gap. Endocrine reviews, 2019, 40 (4): 988-999. doi: 10.1210/er.2018-00284
[4] Muzurović E, Kraljević I, Solak M, Dragnić S, Mikhailidis D.P. Homocysteine and diabetes: role in macrovascular and microvascular complications. J Diabetes Complications, 2021, 35 (3): 107834. doi: 10.1016/j.jdiacomp.2020.107834
[5] Liu L, Xu J, Zhang Z et al. Metabolic homeostasis of amino acids and diabetic kidney disease. Nutrients, 2023, 15 (1): 184.
[6] Zulfania, Khan A, Rehman S, Ghaffar T. Association of homocysteine with body mass index, blood pressure, HbA1c and duration of diabetes in type 2 diabetics. Pak J Med Sci, 2018, 34 (6): 1483-1487. doi: 10.12669/pjms.346.16032
[7] Kumar V, Gulati Y, Giri R et al. Correlation of serum homocysteine with HbA1c and kidney function in type 2 diabetic patients: insights from estimated glomerular filtration rate and renal impairment. International Journal of Research in Medical Sciences, 2024, 13 (1): 235-240. doi: 10.18203/2320-6012.ijrms20244121
[8] Yu C, Wang J, Wang F et al. Inverse association between plasma homocysteine concentrations and type 2 diabetes mellitus among a middle-aged and elderly Chinese population. Nutrition, Metabolism and Cardiovascular Diseases, 2018, 28 (3): 278-284. doi: 10.1016/j.numecd.2017.11.009
[9] Cohen R.M, Holmes Y.R, Chenier T.C, Joiner C.H. Discordance between HbA1c and fructosamine: evidence for a glycosylation gap and its relation to diabetic nephropathy. Diabetes Care, 2003, 26 1): 163-167. doi: 10.2337/diacare.26.1.163